Coherus Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
(in thousands)
| | | | | | |
|---|---|---|---|---|---|
| | Year Ended December 31, | ||||
| · 2025 · · 2024 | |||||
| Net income | $168,024 | | $28,507 | ||
| Other comprehensive income (loss): | | | | ||
| Unrealized gain (loss) on available-for-sale securities, net of tax | | 80 | | | (24) |
| Foreign currency translation adjustments, net of tax | | — | | | (3) |
| Comprehensive income | $168,104 | | $28,480 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.